VolitionRx chief hails importance of colorectal cancer screening test CE mark

1 Views

07/07/23

The boss of cancer diagnostics group VolitionRx (NYSE:VNRX) reckons the awarding of a CE mark for its Nu.Q Colorectal Cancer Screening Triage test could be transformational for the firm.
Chief executive Cameron Reynolds tells Proactive: “This is a very big deal for us. It really shifts the company from an R&D company to a product company.”
“It’s an extremely rewarding time for us and something we’re very happy about”
Reynolds also gives investors a run-through of how the test works and how it will work alongside current cancer screening methods.
On top of that, the VolitionRx boss discusses the progress being made as a whole, including an update on the development facility in Belgium purchased last October.